ASH 2020 | CAPTIVATE: 1-year DFS results from the MRD cohort in CLL
William Wierda
• 1 Dec 2020
William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines 1-year disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the Phase II CAPTIVATE study (NCT02910583) investigating ibrutinib plus venetoclax for first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia. The 1-year DFS in patients received to placebo after ibrutinib plus venetoclax treatment was similar to that of patients continuing ibrutinib, supporting a fixed-duration treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
